Biotech

Startups

Biotech Startups Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 06.12.2022.

Biotechnology
Executive officer
Initial public offering
Management occupations
Medicine
Health care

@rtnarch shared
On Dec 5, 2022
RT @Biotechnology: SonoThera Bags $60M for Ultrasound-Guided, Non-Viral Gene Therapy https://t.co/zAopvk1Kj8 https://t.co/U0yECYVkb3
Open
SonoThera Bags $60M for Ultrasound-Guided, Non-Viral Gene Therapy

SonoThera Bags $60M for Ultrasound-Guided, Non-Viral Gene Therapy

​​​​​​​SonoThera closed its Series A round of financing Monday, counting $60.75 million in earnings and will use these proceeds to advance its ultrasound-guided, non-viral gene therapy ...

@matthewherper shared
On Dec 1, 2022
Next Monday, an STAT in NYC event you don't want to miss. Ivan Cheung, the CEO of Eisai will talk about lecanemab, the new Alzheimer's drug. So will @jasonkarlawish. Then we'll have a panel of STAT's top reporters. $50 -- free for STAT subscribers. https://t.co/VJT29xGNsQ
Open
STAT in NYC: A Look Ahead at Biotech in 2023

STAT in NYC: A Look Ahead at Biotech in 2023

In the markets, and perhaps in the world, doom and gloom pervade. Yet, at the same time, science continues to move forward at a stunning pace, with bi

@BentheFidler shared
On Nov 30, 2022
Sana reshuffles drug pipeline, becoming latest biotech to cut staff https://t.co/SJUn9X5doA by @Lilah_Alvarado $SANA
Open
Sana reshuffles drug pipeline, becoming latest biotech to cut staff

Sana reshuffles drug pipeline, becoming latest biotech to cut staff

The richly funded drugmaker will cut 15% of its workforce, or about 75 employees, as well as stop work on one of its preclinical research programs.

@BiotechWorld shared
On Dec 2, 2022
Vaxxas Appoints Doug Cubbin as Chief Financial Officer https://t.co/DzmSv36HPX
Open
Vaxxas Appoints Doug Cubbin as Chief Financial Officer

Vaxxas Appoints Doug Cubbin as Chief Financial Officer

Vaxxas Appoints Doug Cubbin as Chief Financial Officer - read this article along with other careers information, tips and advice on BioSpace

@ldtimmerman shared
On Dec 5, 2022
Data dilemmas in clinical trials and other hot topics in biopharma. By TR healthtech columnist @DShaywitz https://t.co/JpWDOTiWU8
Open
Hot Topics in Biopharma: Initial Impact of Digital, Data Dilemmas in Clinical Studies, and the Search for ‘New Normal’

Hot Topics in Biopharma: Initial Impact of Digital, Data Dilemmas in Clinical Studies, and the Search for ‘New Normal’

For today: topics relevant to many drug developers (and others): The initial impact of digital The dilemma of data collection in early clinical studies The elusive search for “new normal” ...

@BentheFidler shared
On Nov 30, 2022
Gene editing startup iECURE returns to investors for fresh funding https://t.co/L2poKkuKnt by @gwendolynawu $RARE $DTIL
Open
Gene editing startup iECURE returns to investors for fresh funding

Gene editing startup iECURE returns to investors for fresh funding

The company, which draws on research by Jim Wilson’s lab at UPenn, says the $65 million it raised will support the start of human testing of its lead drug through to initial clinical data.

@WSJVC shared
On Nov 30, 2022
General Catalyst led a $67 million financing round for Vial, which aims to help researchers speed enrollment of clinical trials and run studies more efficiently https://t.co/mA3U25Kuxp
Open
General Catalyst Backs Clinical Trials Startup Vial

General Catalyst Backs Clinical Trials Startup Vial

Venture firm General Catalyst has led a new investment in Vial Health Technology, a startup whose technology and services are designed to help biotechnology companies run faster and ...

@GENbio shared
On Dec 6, 2022
RT @benchling: What’s the next big thing in tech? Working on Biden’s bioeconomy order. Here’s what Benchling co-founder & president @daashu had to say in @GENbio about the role for tech in building up our bioeconomy. https://t.co/2zsHrWvaHz
Open
Why Tech Should Answer the Call of Biden’s Bioeconomy Executive Order

Why Tech Should Answer the Call of Biden’s Bioeconomy Executive Order

President Biden’s executive order to advance our national bioeconomy highlighted the tension between the amazing scientific innovation over the last 10 years and the need for our biotech ...